Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - docetaxel - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol; polysorbate 80; citric acid; nitrogen - docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel sandoz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel sandoz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel sandoz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel sandoz in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of =1cm and < 7cm. docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. docetaxel sandoz is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy. docetaxel sandoz is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. docetaxel sandoz, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol; nitrogen - docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel sandoz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel sandoz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel sandoz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel sandoz in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of =1cm and < 7cm. docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. docetaxel sandoz is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy. docetaxel sandoz is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. docetaxel sandoz, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - docetaxel - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Ireland - English - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - docetaxel anhydrous - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

actavis - docetaxel - concentrate for solution for infusion - 40 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

actavis - docetaxel - concentrate for solution for infusion - 40 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docetaxel 20 mg/ml;   - concentrate for injection - 160 mg/8ml - active: docetaxel 20 mg/ml   excipient: citric acid ethanol polysorbate 80 - breast cancer docetaxel accord is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. adjuvant treatment of breast cancer docetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel accord in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel accord in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel accord in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1 cm and < 7 cm.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docetaxel 20 mg/ml;   - concentrate for injection - 80 mg/4ml - active: docetaxel 20 mg/ml   excipient: citric acid ethanol polysorbate 80 - breast cancer docetaxel accord is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. adjuvant treatment of breast cancer docetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel accord in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel accord in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel accord in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1 cm and < 7 cm.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - docetaxel - solution for infusion - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. docetaxel in combination with trastuzumab, and carboplatin (tch) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. non-small cell lung cancer: docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma. ovarian cancer: docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. prostate cancer: docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.esophageal cancer: docetaxel for the treatment of esophageal cancer. gastric cancer: docetaxel for the treatment of advanced gastric cancer. head and neck (scchn): docetaxel as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck